Tec-Dara Approved: Expanding Access to Innovative Treatment for Myeloma Patients

The U.S. Food and Drug Administration (FDA) approved a new combination treatment using Tecvayli® (teclistamab) and Darzalex® (daratumumab), often called Tec-Dara, for people with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. 

This approval marks another step forward in expanding treatment options for patients whose myeloma has returned or stopped responding to previous treatments. 

Why This Approval Matters 

Until now, bispecific antibody treatments like Tecvayli have typically been used later in the course of myeloma, often for patients whose disease has returned after four or more prior lines of therapy. 

Darzalex, a monoclonal antibody therapy, is commonly used earlier in treatment, including as part of initial therapy or early relapse regimens. 

The newly approved Tec-Dara combination brings these two approaches together, allowing patients to receive a bispecific immunotherapy much earlier in their treatment journey after just one prior line of therapy. 

For many patients at this stage of relapse, CAR T-cell therapy has been one of the main treatment options. While CAR T can be highly effective, it is usually available only at specialized academic medical centers and may require travel, wait times, and complex coordination of care. 

Because Tec-Dara can be administered in many community oncology practices, this approval may help make advanced immune-based therapies more accessible to patients who may not have easy access to CAR T treatment centers. 

What the Clinical Trial Showed

The FDA approval was based on results from a Phase 3 clinical study that included more than 500 patients with relapsed or refractory multiple myeloma who had previously received one to three lines of treatment. 

Participants received either: 

• Tecvayli + Darzalex (Tec-Dara)
• Standard triplet therapies, such as Darzalex with pomalidomide and dexamethasone or Darzalex with bortezomib and dexamethasone. 

Patients receiving the Tec-Dara combination experienced significantly longer progression-free survival compared with those receiving standard therapy: 

• 83% of patients were alive without their disease progressing, compared with 30% of patients receiving standard treatments. 
• In many patients receiving Tec-Dara, the disease did not progress for up to three years. 

Side effects were generally manageable and similar between treatment groups, although infections occurred more often in patients receiving Tec-Dara. Patients also experienced cytokine release syndrome (CRS), an immune reaction that is typically mild and treatable with careful monitoring. 

These findings highlight the potential of combining immune-based therapies to produce deep and durable responses for patients whose myeloma has returned. 

Next Steps for Patients

If you or a loved one is living with multiple myeloma and have experienced relapse, talk with your care team about whether this newly approved combination therapy could be an option for you. 

Questions you may want to ask include: 

• Could Tec-Dara be appropriate for my stage of treatment? 
• How does this option compare with CAR T-cell therapy or other treatments available to me? 
• What side effects should I watch for? 
• How will treatment be given and monitored? 
• Will I be able to receive this therapy at my local treatment center? 

Your healthcare team can help determine whether Tec-Dara may fit into your treatment plan and discuss how it compares with other available options. 

In addition to your care team, the MMRF Patient Navigation Center can offer support in answering these questions and give one‑on‑one guidance tailored for you. The MMRF Education Hub also offers additional materials to help better understand treatment options and navigate you along your myeloma journey.